AbCellera, Teva to discover antibodies targeting undisclosed membrane protein

AbCellera Biologics Inc. (Vancouver, B.C.) will use its antibody screening platform to discover antibodies that modulate the function of an undisclosed membrane protein target selected by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). AbCellera will receive an undisclosed upfront payment and research support and will be eligible for undisclosed development and commercial milestones, plus royalties. AbCellera declined to disclose further details and Teva did not respond to inquiries...